Evaluation of the antithrombogenicity of poly-2-methoxyethylacrylate-coated catheters
- 25 December 2020
- journal article
- research article
- Published by SAGE Publications in The Journal of Vascular Access
- Vol. 23 (1) , 117-122
Abstract
The blood compatibility of indwelling intravascular catheters is facilitated by the use of antithrombogenic materials. Heparin has typically been used for this purpose; however, since heparin-coated catheters are considered combination products, difficulties meeting the relevant Food and Drug Administration safety recommendations have disrupted commercialization. Other issues include coating durability and the occurrence of heparin-induced thrombocytopenia. Polymer coatings are a potential alternative; however, polymer antithrombogenicity in circulating human blood has yet to be demonstrated. The present study aimed to establish the ex vivo antithrombogenicity of a poly-2-methoxyethylacrylate (PMEA) polymer coating applied to a central venous catheter using an artificial human blood circulation system. The present study used an artificial human blood circulation system to conduct an ex vivo evaluation of the antithrombogenicity of poly-2-methoxyethylacrylate (PMEA)-coated catheters. Human blood samples obtained from volunteer donors were loaded into a circulation system fitted with either a PMEA-coated or uncoated catheter. After 3-h, the catheter was removed and examined using scanning electron microscopy. Protein adsorption on the catheter surface was investigated by shredding the catheter that had contacted the blood inside the circulation system and immersing the pieces in 1 mL of 0.5 N NaOH for 2 days. The amount of protein in the 0.5 N NaOH was determined according to the Lowry method. Adherent fibrin, which forms a sheath on the catheter surface, was observed on uncoated, but not PMEA-coated catheters. Furthermore, the amount of protein adsorption was significantly less with PMEA-coated than uncoated catheters (p = 0.043). The present findings demonstrated the antithrombogenicity of PMEA-coated catheters in circulating human blood.Keywords
This publication has 23 references indexed in Scilit:
- International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancerJournal of Thrombosis and Haemostasis, 2012
- Epidemiology and prevention of catheter‐related thrombosis in patients with cancerJournal of Thrombosis and Haemostasis, 2012
- Surface grafting of biocompatible phospholipid polymer MPC provides wear resistance of tibial polyethylene insert in artificial knee jointsOsteoarthritis and Cartilage, 2010
- Clarification of the Blood Compatibility Mechanism by Controlling the Water Structure at the Blood–Poly(meth)acrylate InterfaceJournal of Biomaterials Science, Polymer Edition, 2010
- Heparin-induced thrombocytopeniaJournal of Thrombosis and Haemostasis, 2009
- Bioline® heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: the immune reaction appeared to continue unabatedPerfusion, 2009
- PEEK biomaterials in trauma, orthopedic, and spinal implantsBiomaterials, 2007
- Heparin Activates Antithrombin Anticoagulant Function by Generating New Interaction Sites (Exosites) for Blood Clotting ProteinasesTrends in Cardiovascular Medicine, 2002
- Prevalence and Persistence of Heparin/Platelet Factor 4 Antibodies in Patients with Heparin Coated and Noncoated Ventricular Assist DevicesASAIO Journal, 2000
- Long-term stability in vivo of a thromboresistant heparinized surfaceBiomaterials, 1987